Dr. Marla Danielle Lipsyc-Sharf, MD

Dr. Lipsyc-Sharf practices at UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health.

Dr. Lipsyc-Sharf's NPI, 1689105124, was assigned on March 26, 2017. Dr. Lipsyc-Sharf graduated from Vagelos College of Physicians and Surgeons in 2017. Dr. Lipsyc-Sharf holds California license A188807.

Dr. Lipsyc-Sharf's primary practice is UCLA Santa Monica Medical Center, at 1250 16th Street, Santa Monica, CA 90404 in Los Angeles County. The practice phone is (310) 319-4000.

Dr. Lipsyc-Sharf's primary practice is UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health. Dr. Lipsyc-Sharf is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Lipsyc-Sharf to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lipsyc-Sharf practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Lipsyc-Sharf's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Lipsyc-Sharf is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Lipsyc-Sharf's licenses on file in 2 states: California and Massachusetts.

CMS data shows 2,290 Medicare services from Dr. Lipsyc-Sharf across 18 procedure codes in 2024, for 166 Medicare patients. Medicare paid $40,849 for them. Every service was in an office.

CMS counts 166 Medicare patients who saw Dr. Lipsyc-Sharf in 2024. The largest group is 65 to 74, with 89 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 16% are also on Medicaid. Their average risk score is 2.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lipsyc-Sharf's median patient age at 61, with 79% women.

In 2024, Dr. Lipsyc-Sharf wrote 141 Medicare Part D claims for 35 patients. 85% of them were for generic drugs. CMS names the drug for 77 of them, across 2 drugs with 11 or more claims each, at $172,450 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Lipsyc-Sharf for performance year 2024, reported as part of a group. Dr. Lipsyc-Sharf accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lipsyc-Sharf as offering telehealth.

Dmand AI links 9 papers to Dr. Lipsyc-Sharf, published from 2021 to 2025. 2023 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Colorectal Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Dr. Lipsyc-Sharf has published most often in JAMA Netw Open. Dr. Lipsyc-Sharf's most frequent co-authors are Charles Stewart Fuchs, MD, MPH, Kimmie Ng, MD and Ann H. Partridge, MD, MPH.

CMS Open Payments shows 26 general payments to Dr. Lipsyc-Sharf from 8 drug and device companies from 2020 to 2025. Consulting fees make up the largest share, 70% of the total. Eli Lilly and Company paid the most, $5,400.

Dr. Lipsyc-Sharf graduated from Vagelos College of Physicians and Surgeons in 2017.

Dr. Lipsyc-Sharf is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.